Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
Status:
WITHDRAWN
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC.